% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Fan:292565,
      author       = {Z. Fan$^*$ and D. Edelmann$^*$ and T. Yuan$^*$ and B. C.
                      Köhler and M. Hoffmeister$^*$ and H. Brenner$^*$},
      title        = {{D}eveloping survival prediction models in colorectal
                      cancer using epigenome-wide {DNA} methylation data from
                      whole blood.},
      journal      = {npj precision oncology},
      volume       = {8},
      number       = {1},
      issn         = {2397-768X},
      address      = {[London]},
      publisher    = {Springer Nature},
      reportid     = {DKFZ-2024-01806},
      pages        = {191},
      year         = {2024},
      note         = {#EA:C070#LA:C070#LA:C120#},
      abstract     = {While genome-wide association studies are valuable in
                      identifying CRC survival predictors, the benefit of adding
                      blood DNA methylation (blood-DNAm) to clinical features,
                      including the TNM system, remains unclear. In a multi-site
                      population-based patient cohort study of 2116 CRC patients
                      with baseline blood-DNAm, we analyzed survival predictions
                      using eXtreme Gradient Boosting with a 5-fold nested
                      leave-sites-out cross-validation across four groups:
                      traditional and comprehensive clinical features, blood-DNAm,
                      and their combination. Model performance was assessed using
                      time-dependent ROC curves and calibrations. During a median
                      follow-up of 10.3 years, 1166 patients died. Although
                      blood-DNAm-based predictive signatures achieved moderate
                      performances, predictive signatures based on clinical
                      features outperformed blood-DNAm signatures. The inclusion
                      of blood-DNAm did not improve survival prediction over
                      clinical features. M1 stage, age at blood collection, and N2
                      stage were the top contributors. Despite some prognostic
                      value, incorporating blood DNA methylation did not enhance
                      survival prediction of CRC patients beyond clinical
                      features.},
      cin          = {C070 / C060 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)HD01-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39237753},
      doi          = {10.1038/s41698-024-00689-5},
      url          = {https://inrepo02.dkfz.de/record/292565},
}